Free Trial

Sanford C. Bernstein's Rating of BridgeBio Pharma on 12/11/2025

On December 11, 2025, Sanford C. Bernstein updated its outlook on BridgeBio Pharma (NASDAQ:BBIO) with the action "Initiated Coverage", setting a "Outperform" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Sanford C. Bernstein

DateCompanyAction
10/15/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Set Price Target
10/15/2026
Celestica, Inc. stock logo
CLS
Celestica
Reiterated Rating
10/15/2026
Domino's Pizza Inc stock logo
DPZ
Domino's Pizza
Reiterated Rating
10/15/2026
Fastenal Company stock logo
FAST
Fastenal
Reiterated Rating
10/15/2026
The J. M. Smucker Company stock logo
SJM
J. M. Smucker
Boost Price Target
10/15/2026
RTX Corporation stock logo
RTX
RTX
Lower Price Target
More Ratings From Sanford C. Bernstein